A new social media campaign called #ThinkHand aims to challenge perceptions about what is important for multiple sclerosis patients - and also bring about changes in drug trials. The campaign launched ...
Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results